The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Open accessAbstract
BACKGROUND: A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown. METHODS: Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthritis. FINDINGS: In 40 studies including up to 133,449 individuals, an IL6R SNP (rs7529229) marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala) was associated with increased circulating log interleukin-6 concentration (increase per allele 9·45%, 95% CI 8·34-10·57) as well as reduced C-reactive protein (decrease per allele 8·35%, 95% CI 7·31-9·38) and fibrinogen concentrations (decrease per allele 0·85%, 95% CI 0·60-1·10). This pattern of effects was consistent with IL6R blockade from infusions of tocilizumab (4-8 mg/kg every 4 weeks) in patients with rheumatoid arthritis studied in randomised trials. In 25,458 coronary heart disease cases and 100,740 controls, the IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events (per allele odds ratio 0·95, 95% CI 0·93-0·97, p=1·53×10(-5)). INTERPRETATION: On the basis of genetic evidence in human beings, IL6R signalling seems to have a causal role in development of coronary heart disease. IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials. Genetic studies in populations could be used more widely to help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses. FUNDING: UK Medical Research Council; British Heart Foundation; Rosetrees Trust; US National Heart, Lung, and Blood Institute; Du Pont Pharma; Chest, Heart and Stroke Scotland; Wellcome Trust; Coronary Thrombosis Trust; Northwick Park Institute for Medical Research; UCLH/UCL Comprehensive Medical Research Centre; US National Institute on Aging; Academy of Finland; Netherlands Organisation for Health Research and Development; SANCO; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research Fund; Agentschap NL; European Commission; Swedish Heart-Lung Foundation; Swedish Research Council; Strategic Cardiovascular Programme of the Karolinska Institutet; Stockholm County Council; US National Institute of Neurological Disorders and Stroke; MedStar Health Research Institute; GlaxoSmithKline; Dutch Kidney Foundation; US National Institutes of Health; Netherlands Interuniversity Cardiology Institute of the Netherlands; Diabetes UK; European Union Seventh Framework Programme; National Institute for Healthy Ageing; Cancer Research UK; MacArthur Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“genetic evidence suggests that IL-6 may be causal for atherosclerotic cardiovascular disease, 24,25”
From Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies (GWAS), meta-analysis, exome analysis and single nucleotide polymorphism (SNP) mapping have associated IL-6, IL-6R and gp130 with inflammatory diseases such as RA and coronary artery disease (263–269).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [265]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We also identified associations between IL6R pQTLs and CAD, rheumatoid arthritis and 7 other disease traits (Supplementary Table S12), thereby supporting the findings of the study69.”
From Genetic determinants of plasma protein levels in the Estonian population (2024) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One large study reported a near significant effect ( P = 0.06) of a functional variant causing impaired signalling at the IL-6 receptor with reduced risk of developing diabetes mellitus 44.”
From Type 2 diabetes mellitus and psychological stress — a modifiable risk factor (2017) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“A previous study has shown a link between IL6R and CAD69.”
From Genetic determinants of plasma protein levels in the Estonian population (2024) · cites this paper as [69]
In the citing paper
“Confirming the role of IL-6 in health, in a large Mendelian randomization analysis, the IL6R SNP rs7529229, marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala), was associated with increased circulating IL-6 levels24.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [24]
In the citing paper
“Variants in the IL6R gene have been found to be associated with increased risk of coronary artery disease24, rheumatoid arthritis, atrial fibrillation, and abdominal aortic aneurysm, and with increased susceptibility to asthma, type 1 diabetes, and depression36,37.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [24]
In the citing paper
“CETP inhibitors exert their relatively modest cardioprotective effects on the basis that in addition to their HDL-C raising effects, more potent CETP inhibitors also lower apolipoprotein B 22,23,75 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“The approach outlined here to obtaining a scaling estimate has generally held true for lipid-lowering therapies and risk of cardiovascular disease 22,23,40,92 but there are several potential reasons why the derivation of such a scaling for other therapeutic target-indication pairs may pose a challenge.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“However, using SNPs located in CETP associated with HDL-C at genome-wide significant levels in a drug-target MR suggests that modifying HDL-C via CETP, is likely to reduce risk of CHD 23,103 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“CETP 23 variants associate with of CHD; APOA1 117 variants do not associate with risk of CHD”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“Various statistical methods have been proposed to reduce weak instrument bias due to sample overlap and bias due to winner’s curse (see Section 3) 43– 45 .”
From Guidelines for performing Mendelian randomization investigations (2020) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,762
Haploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,563
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Cited by
Sorted by citations
Items 601–700 of 999
Simonsen, J. R., Järvinen, A., Harjutsalo, V., Forsblom, C. M., Groop, P., & Lehto, M. J. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13138 · Cited by 17
The Risk of Acute Myocardial Infarction in Patients With Gastroesophageal Reflux Disease
Eisa, M., Sandhu, A., Prakash, R., Ganocy, S., & Fass, R. (2020) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19192 · Cited by 18
Grenadyorov, A. S., Zhulkov, M. O., Solovyev, А. А., Oskomov, K. V., Semenov, V. A., Chernyavskiy, A. M., Sirota, D. A., Karmadonova, N. A., Malashchenko, V. V., Litvinova, L. S., et al. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112002 · Cited by 18
How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?
Schooling, C. M., & Zhao, J. V. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00315-3 · Cited by 17
Fiolet, A. T. L., Lin, A., Kwieciński, J., Nolthenius, J. T., McElhinney, P. A., Grodecki, K., Kietselaer, B., Opstal, T. S. J., Cornel, J. H., Knol, R. J. J., et al. (2025) · Heart · doi:10.1136/heartjnl-2024-325527 · Cited by 17
Immune-Inflammation in Atherosclerosis: A New Twist in an Old Tale
Talepoor, A. G., Fouladseresht, H., Khosropanah, S., & Doroudchi, M. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666191016095725 · Cited by 16
A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD
Nowak, K. L., Kakkar, R. K., Devalaraja, M., Lo, L., Park, W., Gobburu, J. V. S., Kling, D. F., Davidson, M., & Chonchol, M. (2020) · Kidney360 · doi:10.34067/kid.0005862020 · Cited by 17
A nationwide study on immunosenescence biomarkers profile in older adults: ELSI-Brazil
Lima-Silva, M. L., Torres, K., Mambrini, J. V. D. M., Brot, N. C., Santos, S. O., Martins‐Filho, O. A., Teixeira‐Carvalho, A., Lima‐Costa, M. F., & Peixoto, S. V. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112433 · Cited by 17
Physical Activity in the Management of Patients with Coronary Artery Disease
Backshall, J., Ford, G. A., Bawamia, B., Quinn, L., Trenell, M. I., & Kunadian, V. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000032 · Cited by 19
Lee, J. S., Chapman, M. J., Piraino, P., Lamerz, J., Schindler, T. H., Cutler, P., & Dernick, G. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500036 · Cited by 18
Inflammation and cardiovascular diseases
Wang, H., & Jing, Z. (2020) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2020.09.003 · Cited by 17
Hu, L., Wang, J., Wu, N., Zhao, X., & Cai, D. (2022) · PeerJ · doi:10.7717/peerj.13852 · Cited by 17
Saburi, A., Karbasi-Afshar, R., Shahmari, A., Madadi, M., & Poursaleh, Z. (2013) · Annals of Cardiac Anaesthesia · doi:10.4103/0971-9784.114242 · Cited by 17
Inflammation and features of the vulnerable plaque: from mechanisms and imaging to outcomes
Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa686 · Cited by 16
Bekkevold, O.-J., Damås, J. K., Brumpton, B. M., & Åsvold, B. O. (2023) · Psychological Medicine · doi:10.1017/s0033291723001290 · Cited by 17
Puig, N., Solé, A., Aguilera‐Simón, A., Griñán, R., Rotllán, N., Camps‐Renom, P., & Benítez, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814325 · Cited by 19
An epithelial gene signature of trans-IL-6 signaling defines a subgroup of type 2-low asthma
Elhusseini, Z. W., Khalenkow, D., Lan, A., van der Molen, T., Brightling, C. E., Papi, A. A., Rabe, K. F., Siddiqui, S., Singh, D., Kraft, M., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02617-w · Cited by 17
Wang, S. E., Viallon, V., Lee, M. A., Dimou, N. L., Hamilton, F., Biessy, C., O’Mara, T. A., Kyrgiou, M., Crosbie, E. J., Truong, T., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105341 · Cited by 16
He, F., Teng, X., Gu, H., Liu, H., Zhou, Z., Zhao, Y., Hu, S., & Zheng, Z. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045623 · Cited by 15
Ayer, A., Mills, C., Donovan, C., Christenson, R. H., Ganz, P., & Dubin, R. F. (2019) · Hemodialysis International · doi:10.1111/hdi.12675 · Cited by 18
on behalf of the IMPROVE study group, Bonomi, A., Veglia, F., Baldassarre, D., Strawbridge, R. J., Golabkesh, Z., Sennblad, B., Leander, K., Smit, A. J., Giral, P., et al. (2020) · Genes and Immunity · doi:10.1038/s41435-019-0090-z · Cited by 16
Zegeye, M. M., Andersson, J. S. O., Wennberg, P., Repsilber, D., Sirsjö, A., & Ljungberg, L. U. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315793 · Cited by 16
Li, S., Chen, L., & Lv, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905936 · Cited by 17
The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.02.046 · Cited by 16
Cholesterol and inflammation: The lesser the better in atherothrombosis
Rocha, V. Z., & Santos, R. D. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318772936 · Cited by 15
Wang, Y., Tian, F., Qian, Z. M., Ran, S., Zhang, J., Wang, C., Chen, L., Zheng, D., Vaughn, M. G., Tabet, M., et al. (2024) · Nutrients · doi:10.3390/nu16203553 · Cited by 15
Namkung, H., Thomas, K. L., Hall, J., & Sawa, A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.025 · Cited by 17
Genetically proxied IL-6 receptor inhibition is associated with increased risk of atopic dermatitis
Zhao, S. S., & Yiu, Z. Z. N. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.05.016 · Cited by 15
An in-depth review of AI-powered advancements in cancer drug discovery
Le, M. H. N., Nguyen, P. K., Nguyen, T. P. T., Nguyen, H. Q., Tam, D. N. H., Huynh, H. H., Huynh, P. K., & Le, N. Q. K. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167680 · Cited by 15
Rare damaging CCR2 variants are associated with lower lifetime cardiovascular risk
Georgakis, M. K., Malik, R., Bounkari, O. E., Hasbani, N. R., Li, J., Huffman, J. E., Shakt, G. E., Tack, R. W. P., Kimball, T. N., Asare, Y., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01456-2 · Cited by 16
Mahmood, Z., Davidsson, A., Olsson, E., Leanderson, P., Lundberg, A. K., & Jonasson, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-78286-2 · Cited by 16
Niu, P., Wang, X., & Xu, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.679363 · Cited by 14
Akinyelure, O. P., Colantonio, L. D., Chaudhary, N. S., Jaeger, B. C., Judd, S. E., Cushman, M., Zakai, N. A., Kabagambe, E. K., Howard, V. J., Safford, M. M., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.07.001 · Cited by 15
Jahromi, G. G., & Rezaei, N. (2025) · Heart and Mind · doi:10.4103/hm.hm-d-24-00076 · Cited by 15
von Känel, R., Mills, P. J., Dimsdale, J. E., Ziegler, M. G., Allison, M., Patterson, T. L., Ancoli‐Israel, S., Pruitt, C., Grant, I., & Mausbach, B. T. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa079 · Cited by 17
Sherman, B. T., Hu, X., Singh, K., Haine, L., Rupert, A. W., Neaton, J. D., Lundgren, J. D., Imamichi, T., Chang, W., & Lane, H. C. (2020) · AIDS · doi:10.1097/qad.0000000000002738 · Cited by 15
Anti-inflammatory strategies for atherosclerotic artery disease
Agnello, F. G., & Capodanno, D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2036717 · Cited by 14
Bonacina, F., Costanzo, A. D., Genkel, V. V., Kong, X. Y., Kroon, J., Stimjanin, E., Tsiantoulas, D., & Grootaert, M. O. J. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.021 · Cited by 14
An MBPhD programme in the UK: the UCL experience
Stewart, G. W. (2012) · Clinical Medicine · doi:10.7861/clinmedicine.12-6-526 · Cited by 14
Cytokine-associated fatigue prior to, during, and post-chemotherapy for breast cancer
Cohen, R. A., Gullett, J. M., Woods, A. J., Porges, E. C., Starkweather, A. R., Jackson‐Cook, C. K., Kelly, D. L., & Lyon, D. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.577001 · Cited by 14
Pretenders and Contenders: Inflammation, C‐Reactive Protein, and Interleukin‐6
Daniels, L. B. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007490 · Cited by 13
Meyre, P. B., Aeschbacher, S., Blum, S., Reichlin, T., Haller, M. L., Rodondi, N., Müller, A. S., Bernheim, A., Beer, J. H., Moschovitis, G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62218-7 · Cited by 13
Forzano, I., Florimonte, D., Narciso, V., Canonico, M. E., Castiello, D. S., Manzi, L., Cristiano, S., Spinelli, A. M., Vallone, D. M., D’Alconzo, D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238334 · Cited by 17
Dang, X., Liu, J., Zhang, Z., & Luo, X. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03160-3 · Cited by 12
Wu, J., Chen, X., Li, R., Lu, Q., Ba, Y., Fang, J. M., Liu, Y., Li, R., Liu, Y., Wang, Y., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155994 · Cited by 14
Pugliesi, A., Oliveira, D., Filho, V. A. D. S., Machado, J. D. O., Pereira, A. G., Bichuette, J. D. C. S., Sachetto, Z., de Carvalho, L. S. F., & Bértolo, M. B. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152563 · Cited by 14
Celeski, M., Segreti, A., Crisci, F., Cricco, R., Piscione, M., Gioia, G. D., Nusca, A., FOSSATI, C., Pigozzi, F., Ussia, G. P., et al. (2024) · Biomolecules · doi:10.3390/biom14121630 · Cited by 13
Ghazi, L., Baker, J. V., Sharma, S., Jain, M. K., Palfreeman, A., Necsoi, C., Murray, D. D., Neaton, J. D., & Drawz, P. E. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz132 · Cited by 13
Li, J., Wang, C., Liu, J., Yu, Y., Liu, Y., Peng, Q., Liu, H., & Guan, X. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06370-5 · Cited by 12
Genetic IL-6 Signaling Modifies Incident Coronary Artery Disease Risk in Chronic Kidney Disease
Yu, Z., Zekavat, S. M., Honigberg, M. C., & Natarajan, P. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.020 · Cited by 13
Biologics and Cardiovascular Disease
Taunay, J. V., Albelda, M. T., Frias, J. C., & Lipinski, M. J. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000595 · Cited by 14
Parsa, H., Faghihi, M., Kardar, G. A., & Imani, A. (2018) · General Physiology and Biophysics · doi:10.4149/gpb_2017049 · Cited by 13
Lin, J., Wang, Y., Wang, Y., & Pan, Y. (2020) · Neurological Research · doi:10.1080/01616412.2019.1710404 · Cited by 13
Using Mendelian randomization to assess and develop clinical interventions: limitations and benefits
Burgess, S., & Mälarstig, A. (2013) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.14 · Cited by 13
Antibody-based immunotherapy targeting cytokines and atherothrombotic cardiovascular diseases
Ait‐Oufella, H., Libby, P., & Tedgui, A. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2019.11.001 · Cited by 13
Hamilton, F., Schurz, H., Yates, T., Gilchrist, J. J., Möller, M., Naranbhai, V., Ghazal, P., Timpson, N. J., Parks, T., & Pollara, G. (2023) · medRxiv · doi:10.1101/2023.02.07.23285472 · Cited by 13
Risk factors for cardiovascular events and incident hospital-treated diabetes in the population
Khalili, P. (2012) · Örebro University Library (Örebro University) · Cited by 13
deGoma, E. M., Walsh, J., & Georgakis, M. K. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.125.005103 · Cited by 13
Pah, A.-M., Serban, S., Mateescu, D.-M., Cotet, I.-G., Mureșan, C.-O., Ilie, A. C., Buleu, F. N., Craciun, M.-L., Crișan, S., & Avram, A. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238610 · Cited by 12
Plasma proteomics and lung function in four community-based cohorts
Rydell, A., Nowak, C., Janson, C., Lisspers, K., Ställberg, B., Iggman, D., Leppert, J., Hedberg, P., Sundström, J., Ingelsson, E., et al. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106282 · Cited by 13
Advanced detection of coronary artery disease via deep learning analysis of plasma cytokine data
Shoaib, M. A., Junaid, A., Husnain, G., Qadir, M., Ghadi, Y. Y., Askar, S., & Abouhawwash, M. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1365481 · Cited by 14
Gordillo‐Marañón, M., Schmidt, A. F., Warwick, A., Tomlinson, C., Ytsma, C. R., Engmann, J., Torralbo, A., Maclean, R., Sofat, R., Langenberg, C., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00625-5 · Cited by 12
Promise and Peril of a Genotype‐First Approach to Mendelian Cardiovascular Disease
Asatryan, B., Murray, B. A., Tadros, R., Rieder, M., Shah, R. A., Dabbagh, G. S., Landstrom, A. P., Dobner, S., Munroe, P. B., Haggerty, C. M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033557 · Cited by 12
Drug repurposing opportunities for breast cancer and seven common subtypes
Lin, Y., Wang, S., Zhang, Y., She, J., Zhang, Y., Zhao, R., Qi, Z., Yang, Q., Zhang, L., & Yang, Q. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106652 · Cited by 12
Zorc, R., Redmond, C., Sylvester, M., Maclean, M. J., Almeida, L. Y., Quinn, K. A., Tomelleri, A., Campochiaro, C., Dagna, L., Gutierrez‐Rodrigues, F., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.01.049 · Cited by 13
Rosenson, R. S., & Köenig, W. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6642-9 · Cited by 12
Li, J., Gong, J., Li, X., Shen, L., Xie, Y., & Zhang, R. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27433 · Cited by 12
Campos, L. P., Graciolo, V., SOUSA, M. D. L. F. D., Martins, B. R., de Souza, S. W., Alberton, D., Picheth, G., & Rego, F. G. D. M. (2019) · Genetics and Molecular Research · doi:10.4238/gmr18260 · Cited by 12
Zhou, M., Dai, W., Cui, Y., Liu, H., & Li, Y. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.27 · Cited by 12
Saeed, M., Tapia, G., Ariansen, I., Stene, L. C., Seljeflot, I., Tell, G. S., Skrivarhaug, T., & Joner, G. (2021) · Diabetes Care · doi:10.2337/dc20-1712 · Cited by 12
Poppelaars, F., da Costa, M. G., Eskandari, S. K., Damman, J. J., & Seelen, M. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-95714-z · Cited by 12
Is calcium a link between inflammatory bone resorption and heart disease?
Klein, G. L. (2022) · eLife · doi:10.7554/elife.83841 · Cited by 13
Chitin enhances obese inflammation ex vivo
Huang, C., Beasley, K. N., Acevedo, E. O., Franco, R. L., Jones, T. L., Mari, D. C., & Shibata, Y. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.09.005 · Cited by 12
Tocilizumab increases EPC regeneration in rheumatoid arthritis
Patschan, S. A., Nemirovsky, K., Henze, E., Scholze, J. E., Müller, G., & Patschan, D. (2014) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2014.926985 · Cited by 12
Xuan, L., Hou, Y., Wang, T., Li, M., Zhao, Z., Lu, J., Xu, Y., Chen, Y., Qi, L., Wang, W., et al. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1165-4 · Cited by 12
Harada, P. H. N., Benseñor, I. M., Bittencourt, M. S., Nasir, K., Blaha, M. J., Jones, S. R., Toth, P. P., & Lotufo, P. A. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.09.006 · Cited by 12
Chang, X.-W., Qin, Y., Jin, Z., Xi, T.-F., Yang, X., Lu, Z.-H., Tang, Y., Cai, W., Shao-jun, C., & Xie, D. (2015) · PubMed Central · Cited by 12
Tocilizumab in the treatment of myocardial infarction
Carroll, M. B. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1427457 · Cited by 12
Mendelian randomization: a premature burial?Preprint
Smith, G. D. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/021386 · Cited by 12
Ferrante, G., & Condorelli, G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy233 · Cited by 12
Genetic determinants of plasma protein levels in the Estonian population
Kalnapenkis, A., Jõeloo, M., Lepik, K., Kukuškina, V., Kals, M., Alasoo, K., Estonian Biobank Research Team, Metspalu, A., Milani, L., Nelis, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57966-3 · Cited by 11
Nooti, S., Rai, V., Radwan, M., Thankam, F., Singh, H., Chatzizisis, Y., & Agrawal, D. (2023) · Cardiology and Cardiovascular Medicine · doi:10.26502/fccm.92920338 · Cited by 10
Song, W., Li, Y., Yao, Y., Sun, S., Guan, X., & Wang, B. (2024) · BMC Cancer · doi:10.1186/s12885-024-12449-6 · Cited by 12
Zhao, S. S., & Burgess, S. (2024) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2024.101967 · Cited by 10
Treating Dyslipidemias: Is Inflammation the Missing Link?
Papoutsidakis, N., Deftereos, S., Γιαννόπουλος, Γ., Panagopoulou, V., & Bouras, G. (2014) · Medicinal Chemistry · doi:10.2174/1573406410666140318101936 · Cited by 11
Terapias antiinflamatorias para la enfermedad cardiovascular: vías de señalización y mecanismos
Martínez‐Hervás, S., & Navarro, H. G. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2019.02.022 · Cited by 11
Stress-induced differential gene expression in cardiac tissue
de Carvalho, A. E. T. S., Cordeiro, M. A. S., Rodrigues, L. S., Ortolani, D., & Spadari, R. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-88267-8 · Cited by 11
The Inflammatory Pattern of Chronic Limb-Threatening Ischemia in Muscles: The TNF-α Hypothesis
Caicedo, D., Álvarez, C. V., Pérez-Romero, S., & Devesa, J. (2022) · Biomedicines · doi:10.3390/biomedicines10020489 · Cited by 11
Barrows, I. R., Devalaraja, M., Kakkar, R. K., Chen, J., Gupta, J., Rosas, S. E., Saraf, S. L., He, J., Go, A. S., Raj, D. S., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025627 · Cited by 11
Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders
Schmidt, A. F., Finan, C., Chopade, S., Ellmerich, S., Rossor, M. N., Hingorani, A. D., & Pepys, M. B. (2024) · Open Biology · doi:10.1098/rsob.230419 · Cited by 11
Self-citationHuang, M.-Y., Wang, L., Ma, H., Wang, J., & Xiang, M. (2013) · DNA and Cell Biology · doi:10.1089/dna.2013.2148 · Cited by 11
Extrarenal atherosclerotic disease blunts renal recovery in patients with renovascular hypertension
Khangura, K. K., Eirin, A., Kane, G. C., Misra, S., Textor, S. C., Lerman, A., & Lerman, L. O. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000160 · Cited by 11
Pathophysiology of Diastolic Dysfunction in Chronic Heart Failure
Segers, V. F. M., & Keulenaer, G. W. D. (2013) · Future Cardiology · doi:10.2217/fca.13.53 · Cited by 11
Genetic markers of inflammation may not contribute to metabolic traits in Mexican children
Vashi, N., Stryjecki, C., Peralta‐Romero, J., Suarez, F., Gómez-Zamudio, J. H., Burguete-García, A. I., Cruz, M., & Meyre, D. (2016) · PeerJ · doi:10.7717/peerj.2090 · Cited by 11
Genética de la cardiopatía isquémica: del conocimiento actual a las implicaciones clínicas
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.02.033 · Cited by 11
Reducing residual cardiovascular risk with novel therapies
Davidson, M. H. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000672 · Cited by 11
Yu, Z., Zekavat, S. M., Haidermota, S., Bernardo, R. C., MacDonald, B. T., Libby, P., Finucane, H. K., & Natarajan, P. (2022) · Science Advances · doi:10.1126/sciadv.abl4602 · Cited by 11
Zhou, J., Chen, X., Ye, H., Peng, P., Ba, Y., Yang, X., Huang, X., Lu, Y., Jiang, X., Lian, J., et al. (2014) · BioMed Research International · doi:10.1155/2014/504727 · Cited by 11
Allergies are associated with arterial changes in young children
Evelein, A. M. V., Visseren, F. L. J., van der Ent, C. K., Grobbee, D. E., & Uiterwaal, C. S. P. M. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314554863 · Cited by 11
Hansen, P., Nelveg-Kristensen, K., Rasmussen, H., Torp-Pedersen, C., Køber, L., Nielsen, C., & Enevold, C. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0068-2 · Cited by 9
Metadata
- Authors
- Swerdlow, D. I.
- Affiliations
- University College London (GB)
- Corresponding author
- Daniel I. Swerdlow
- ORCID
- Daniel I. Swerdlow
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 379
- Issue
- 9822
- Pages
- 1214-1224
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3316968
- OpenAlex
- W2143727405
- Cited by
- 1,146
- References
- 100
- Citations by year
- 2026: 78 · 2025: 86 · 2024: 94 · 2023: 89 · 2022: 84 · 2021: 110 · 2020: 89 · 2019: 80 · 2018: 74 · 2017: 77 · 2016: 67 · 2015: 56 · 2014: 63 · 2013: 65 · 2012: 32
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion, cc-by)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- MRC population health scientist fellowship (G0802432)
- National Institutes of Health (NIH), the MRC, and the British Heart Foundation (BHF (RG/10/12/28456)
- BHF (Schillingford) clinical training fellowship (FS/07/011)
- US National Heart, Lung, and Blood Institute (HHSN268200900009C)
- National Human Genome Research Institute (U01HG005152)
- Cancer Research UK (C1298/A8362, C150/A5660)
- IKEM (Czech Republic) (00023001)
- National Institute for Healthy Ageing (05060810)
- NIH/NHLBI (5215810-55000000041)
- BHF (RG 08/008 and PG/07/133/24260, RG/04/003)
- Netherlands Organisation for Health Research and Development (90700342)
- BHF senior fellowship (FS 05/125)
- British Heart Foundation (RG/10/12/28456)
- contract no. (HHSN268200625226C)
- NHLBI in collaboration with MESA investigators (N01 HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, and RR-024156)
- Wellcome Trust (064947/Z/01/Z and 081081/Z/06/Z)
- National Institute on Aging (1R01 AG23522-01)
- Intramural Research Program of the National Institute on Aging, NIH, Department of Health and Human Services (Z01 AG000954-06, ISGS (R01 NS42733), (R01 NS39987), Z01 AG000015-50)
- European Commission (QLG1-CT-2002-00896)
- Dutch Kidney Foundation (Grant E033)
- GENECURE (FP-6 LSHM CT 2006 037697)
- NIH (grant LM010098)
- The Netherlands Organisation for Health Research and Development (grant 916.761.70)
- European Union's Seventh Framework Programme (FP7/2007-2013)
- NHLBI (RFP-NHLBI-WH-11-10, HL36310)
- Veni grant Organization for Scientific Research (NWO) (2001.064)
- NIH; National Institute on Aging (AG13196)
- MRC (grant NHLBI 33014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- IL-6 receptor, tocilizumab, coronary artery disease, primary prevention, C-reactive protein, fibrinogen, rheumatoid arthritis, genetic variants, monoclonal antibodies
- MeSH terms
- Coronary Disease, Gene Frequency, Genotype, Humans, Phenotype, Genetic Variation, Signal Transduction, Randomized Controlled Trials as Topic, Treatment Outcome, Inflammation Mediators, Receptors, Interleukin-6, Polymorphism, Single Nucleotide, Genetic Association Studies, Mendelian Randomization Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
